Key Insights

Highlights

Success Rate

83% trial completion

Published Results

24 trials with published results (13%)

Research Maturity

105 completed trials (59% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

11.8%

21 terminated out of 178 trials

Success Rate

83.3%

-3.2% vs benchmark

Late-Stage Pipeline

22%

39 trials in Phase 3/4

Results Transparency

23%

24 of 105 completed with results

Key Signals

24 with results83% success21 terminated

Data Visualizations

Phase Distribution

92Total
Not Applicable (34)
Early P 1 (1)
P 1 (4)
P 2 (14)
P 3 (13)
P 4 (26)

Trial Status

Completed105
Unknown24
Terminated21
Recruiting13
Withdrawn6
Not Yet Recruiting4

Trial Success Rate

83.3%

Benchmark: 86.5%

Based on 105 completed trials

Clinical Trials (178)

Showing 20 of 20 trials
NCT04821661CompletedPrimary

T2 and SeptiCyte RAPID Duration Project

NCT02633124Not ApplicableTerminatedPrimary

Preventing Catheter-related Bacteremia When Administering Injectable Medications in Premature Infants.

NCT05770622Phase 4Recruiting

Improving Therapeutic Drug Monitoring and Dosing for Vancomycin in Young Infants With Infections (VANCAPP) (Part 2)

NCT07134751Recruiting

Febrile Infants Swedish Study

NCT05184764Phase 1CompletedPrimary

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

NCT07486362RecruitingPrimary

Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge

NCT06838598Recruiting

Structural and Microbiological Characterization of Arterial Catheter Biofilm in ICU's Patients Using Optical Coherence Tomography

NCT04478721Phase 3CompletedPrimary

Temocillin vs Meropenem for the Targeted Treatment of Bacteraemia Resistant to Third Gen Cephalosporins

NCT04673175Phase 4Terminated

Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation

NCT05741424Not ApplicableCompletedPrimary

Impact of BacT/Alert® VIRTUO®, BioFire® Blood Culture Identification 2-BCID2 and REVEAL® (bioMérieux) on the Optimization of Antibiotic Therapy for Gram-negative Bacteremia in the ICU

NCT02026895Not ApplicableCompleted

Virulence of Staphylococcus Lugdunensis in Severe Infections

NCT06563609Not ApplicableTerminated

Combined Rehabilitation and Nutritional Support vs. Standard Care in In-Hospital Endocarditis Treatment

NCT06457386Not ApplicableRecruiting

Echocardiography Versus no Echocardiography in S. Aureus Bacteraemia and VIRSTA Score < 3

NCT07240077Phase 4Not Yet RecruitingPrimary

Beta-lactam Plus Levofloxacin to Enhance Therapy in Streptococcal Septicemia

NCT04565691Not ApplicableActive Not RecruitingPrimary

Bacteremia From Periodontal Treatment to Elucidate the Underpinnings of Sepsis

NCT07183410Not Yet RecruitingPrimary

Impact of Blood Cultures Drawn From Arterial Lines on the Incidence of Contamination, Detection of Bacteremia, and Blood Culture Volume

NCT05721781Not ApplicableRecruitingPrimary

Reducing Risk for Infective Endocarditis

NCT07126106RecruitingPrimary

Prospective Validation of GRADY: A Machine Learning Model for Early Sepsis and Bacteremia Detection in ICU Patients

NCT04825132Not ApplicableCompleted

Infectious Diseases in Aged Population

NCT03671967Phase 4Recruiting

PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)

Scroll to load more

Research Network

Activity Timeline